0 Commentarii
0 Distribuiri
86 Views
0 previzualizare
Căutare
Descoperă oameni noi, creează noi conexiuni și faceti-va noi prieteni
- Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
- Peptide Based Cancer Therapeutics Market Growth Driven by Expanding Infrastructure Development Across Industries upto 2027According to the research report published by Polaris Market Research, the Global Peptide Based Cancer Therapeutics Market Size Is Expected To Reach USD 17.18 Billion By 2027, at a CAGR of 9.1% during the forecast period. Report Overview An extensive analysis of the quickly expanding market can be found in the research report Peptide Based Cancer Therapeutics Market: By Size, Latest...0 Commentarii 0 Distribuiri 479 Views 0 previzualizare
- Peptide Based Cancer Therapeutics Market Outlook of Key Countries: A Comprehensive Analysis forecast 2032The quantitative market research report published by Polaris Market Research on Peptide Based Cancer Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Goserelin, Bortezomib, Leuprorelin, and Others); By Cancer Type (Lung, Breast, Colorectal, Prostrate, Skin, and Stomach Cancer); By Mode of Mechanism (Inhibitory, Necrosis Inducing, and Pro-Apoptotic Peptides),...0 Commentarii 0 Distribuiri 363 Views 0 previzualizare
- Peptide Based Cancer Therapeutics Market Size, Overview, Share and Forecast 2031The Peptide Based Cancer Therapeutics Market in 2023 is US$ 10.1 billion, and is expected to reach US$ 18.72 billion by 2031 at a CAGR of 8%. FutureWise Research published a report that analyzes Peptide Based Cancer Therapeutics Market trends to predict the market's growth. The report begins with a description of the business environment and explains the commercial summary of the chain...0 Commentarii 0 Distribuiri 525 Views 0 previzualizare
- Peptide-based Cancer Therapeutics Market, Competitive Landscape, Revenue Analysis by Fact MRExpanding at a CAGR of 7.8%, the global peptide-based cancer therapeutics market is forecasted to increase from a valuation of US$ 10.1 billion in 2023 to US$ 21.4 billion by the end of 2033. A rise in research and development activities and continuous clinical trials are presenting lucrative prospects for bortezomib drug manufacturer. Peptide-based cancer therapeutics represent a promising...0 Commentarii 0 Distribuiri 940 Views 0 previzualizare